2024-514213-35-00招募中1 期
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
AstraZeneca Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (3)
Loading locations...
相似试验
已完成
不适用
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.Idiopathic pulmonary fibrosisidiopathische fibrosepulmonary diseases.NL-OMON40896Moerae Matrix, Inc48
已完成
不适用
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orallyNL-OMON48072OP2 Drugs12
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseasesKCT0004026Kyung Dong Pharmaceutical80
进行中（未招募）
不适用
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2007-002912-24-DEBayer HealthCare AG16
进行中（未招募）
1 期
A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjectsCTIS2023-507409-32-00Cybin IRL Limited72